vs
Side-by-side financial comparison of Eastman Chemical Company (EMN) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
Eastman Chemical Company is the larger business by last-quarter revenue ($2.0B vs $1.1B, roughly 1.8× PERRIGO Co plc). Eastman Chemical Company runs the higher net margin — 5.3% vs -127.8%, a 133.1% gap on every dollar of revenue. On growth, PERRIGO Co plc posted the faster year-over-year revenue change (-2.5% vs -13.8%). Over the past eight quarters, PERRIGO Co plc's revenue compounded faster (1.3% CAGR vs -8.6%).
Eastman Chemical Company is an American chemical products manufacturer based in Kingsport, Tennessee. Founded in 1920, it was formerly a subsidiary of Kodak until 1994. The company is an independent global specialty materials company that produces a broad range of advanced materials, chemicals and fibers for everyday purposes. It operates 36 manufacturing sites worldwide and employs approximately 14,000 people. In 2023, Eastman had sales revenue of approximately $9.21 billion.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
EMN vs PRGO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.0B | $1.1B |
| Net Profit | $105.0M | $-1.4B |
| Gross Margin | 17.1% | 32.6% |
| Operating Margin | — | -116.0% |
| Net Margin | 5.3% | -127.8% |
| Revenue YoY | -13.8% | -2.5% |
| Net Profit YoY | -42.3% | -3093.9% |
| EPS (diluted) | $0.93 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | $1.1B | ||
| Q3 25 | $2.2B | $1.0B | ||
| Q2 25 | $2.3B | $1.1B | ||
| Q1 25 | $2.3B | $1.0B | ||
| Q4 24 | $2.2B | $1.1B | ||
| Q3 24 | $2.5B | $1.1B | ||
| Q2 24 | $2.4B | $1.1B |
| Q1 26 | $105.0M | — | ||
| Q4 25 | $105.0M | $-1.4B | ||
| Q3 25 | $47.0M | $7.5M | ||
| Q2 25 | $140.0M | $-8.4M | ||
| Q1 25 | $182.0M | $-6.4M | ||
| Q4 24 | $330.0M | $-44.4M | ||
| Q3 24 | $180.0M | $-21.0M | ||
| Q2 24 | $230.0M | $-108.4M |
| Q1 26 | 17.1% | — | ||
| Q4 25 | 17.1% | 32.6% | ||
| Q3 25 | 19.7% | 36.1% | ||
| Q2 25 | 22.1% | 34.4% | ||
| Q1 25 | 24.8% | 37.6% | ||
| Q4 24 | 24.7% | 33.9% | ||
| Q3 24 | 24.6% | 37.2% | ||
| Q2 24 | 25.3% | 37.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | -116.0% | ||
| Q3 25 | 6.1% | 7.0% | ||
| Q2 25 | 7.4% | 4.3% | ||
| Q1 25 | 11.0% | 4.5% | ||
| Q4 24 | 13.2% | 10.0% | ||
| Q3 24 | 11.4% | 7.4% | ||
| Q2 24 | 12.1% | -2.5% |
| Q1 26 | 5.3% | — | ||
| Q4 25 | 5.3% | -127.8% | ||
| Q3 25 | 2.1% | 0.7% | ||
| Q2 25 | 6.1% | -0.8% | ||
| Q1 25 | 7.9% | -0.6% | ||
| Q4 24 | 14.7% | -3.9% | ||
| Q3 24 | 7.3% | -1.9% | ||
| Q2 24 | 9.7% | -10.2% |
| Q1 26 | $0.93 | — | ||
| Q4 25 | $0.93 | $-10.23 | ||
| Q3 25 | $0.40 | $0.05 | ||
| Q2 25 | $1.20 | $-0.06 | ||
| Q1 25 | $1.57 | $-0.05 | ||
| Q4 24 | $2.81 | $-0.32 | ||
| Q3 24 | $1.53 | $-0.15 | ||
| Q2 24 | $1.94 | $-0.79 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $566.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $6.0B | $2.9B |
| Total Assets | $14.9B | $8.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $566.0M | — | ||
| Q4 25 | $566.0M | — | ||
| Q3 25 | — | $432.1M | ||
| Q2 25 | — | $454.2M | ||
| Q1 25 | — | $409.9M | ||
| Q4 24 | $837.0M | $558.8M | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $542.8M |
| Q1 26 | $6.0B | — | ||
| Q4 25 | $6.0B | $2.9B | ||
| Q3 25 | $5.8B | $4.4B | ||
| Q2 25 | $5.8B | $4.5B | ||
| Q1 25 | $5.9B | $4.4B | ||
| Q4 24 | $5.8B | $4.3B | ||
| Q3 24 | $5.7B | $4.6B | ||
| Q2 24 | $5.6B | $4.5B |
| Q1 26 | $14.9B | — | ||
| Q4 25 | $14.9B | $8.5B | ||
| Q3 25 | $15.0B | $10.1B | ||
| Q2 25 | $15.2B | $10.1B | ||
| Q1 25 | $15.0B | $9.8B | ||
| Q4 24 | $15.2B | $9.6B | ||
| Q3 24 | $15.1B | $11.2B | ||
| Q2 24 | $14.9B | $10.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $175.4M |
| Free Cash FlowOCF − Capex | — | $148.6M |
| FCF MarginFCF / Revenue | — | 13.4% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $502.0M | $175.4M | ||
| Q3 25 | $402.0M | $51.7M | ||
| Q2 25 | $233.0M | $75.9M | ||
| Q1 25 | $-167.0M | $-64.5M | ||
| Q4 24 | $540.0M | $312.6M | ||
| Q3 24 | $396.0M | $42.2M | ||
| Q2 24 | $367.0M | $9.5M |
| Q1 26 | — | — | ||
| Q4 25 | $390.0M | $148.6M | ||
| Q3 25 | $265.0M | $29.8M | ||
| Q2 25 | $83.0M | $56.7M | ||
| Q1 25 | $-314.0M | $-90.0M | ||
| Q4 24 | $361.0M | $274.9M | ||
| Q3 24 | $276.0M | $15.1M | ||
| Q2 24 | $252.0M | $-18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 19.8% | 13.4% | ||
| Q3 25 | 12.0% | 2.9% | ||
| Q2 25 | 3.6% | 5.4% | ||
| Q1 25 | -13.7% | -8.6% | ||
| Q4 24 | 16.1% | 24.2% | ||
| Q3 24 | 11.2% | 1.4% | ||
| Q2 24 | 10.7% | -1.8% |
| Q1 26 | — | — | ||
| Q4 25 | 5.7% | 2.4% | ||
| Q3 25 | 6.2% | 2.1% | ||
| Q2 25 | 6.6% | 1.8% | ||
| Q1 25 | 6.4% | 2.4% | ||
| Q4 24 | 8.0% | 3.3% | ||
| Q3 24 | 4.9% | 2.5% | ||
| Q2 24 | 4.9% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | 4.78× | — | ||
| Q3 25 | 8.55× | 6.89× | ||
| Q2 25 | 1.66× | — | ||
| Q1 25 | -0.92× | — | ||
| Q4 24 | 1.64× | — | ||
| Q3 24 | 2.20× | — | ||
| Q2 24 | 1.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EMN
Segment breakdown not available.
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
